Lung cancer drugs
These companies develop drugs for lung cancer, often targeting genes like EGFR, ALK, ROS1, MET or KRAS.
−12.3%
over 1 year · S&P 500 +11.6%
Key indicators
Health
50 / 100
Fragile
Solid
Up over 1 year
3 of 8
Volatility
82%
Calm
Choppy
Profitability
−65%
Low
High
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 10 companies
SMMT
−24.9%
IOVA
+205.5%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
S
Summit Therapeutics
SMMT
61.7%
−24.9%
I
Iovance Biotherapeutics
IOVA
17.9%
+205.5%
N
Nuvation Bio
NUVB
7.1%
−19.1%
O
Oric Pharmaceuticals
ORIC
4.5%
−37.0%
C
Cullinan Therapeutics
CGEM
3.5%
+23.1%
A
ArriVent BioPharma
AVBP
3.2%
−35.6%
B
BlossomHill Therapeutics
BLSM
2.2%
A
AstraZeneca
AZN
H
HUTCHMED
HCM
−2.5%
Z
Zai Lab
ZLAB
+12.4%